The Institute for Bioanalytics to Develop Anti-Doping Tests
for the 2004 Olympic Games
Branford, CT, August 5, 2003- The Institute for Bioanalytics, LLC (IBA) announces the receipt of a research grant of $250,000 from the United States Anti-Doping Agency (USADA) for the development of biological tests that can detect the use of performance enhancing substances by athletes. These novel tests are being developed for use at future Olympic Games. USADA’s Senior Managing Director, Dr. Larry Bowers states that the collaboration between IBA and USADA holds “great potential for the development of new drug screening methods to assure the integrity of national and international athletic competition.”
IBA is a world leader in providing multiplex assay development strategies to the pharmaceutical and biotechnology industries. The Multiplex technology allows researchers to simultaneously detect multiple substances in a single blood or urine sample. “The uniqueness of this testing allows a large amount of information to be gleaned from a small volume of a clinical specimen,” states Dr. Jan Wasley, IBA’s Chief Scientific Officer.
USADA, the independent anti-doping agency for Olympic sports in the United States, has the full authority for the testing and education of Olympic athletes, adjudication of alleged doping violations, and research into prohibited substances and methods used for performance enhancement. Doping violates the ethics of both sport and medical science and is prohibited by the US Olympic Committee. USADA has budgeted $2 million annually for anti-doping research. “The grants we have awarded so far have set a strong foundation for the fight against doping on the world scene,” states Dr. Bowers.
IBA is a privately held biotechnology company whose mission is the delivery of customized bioanalytical method development services to its global client base. IBA can enhance the discovery and development of new drug targets through its expertise in biotechnology, proteomics, functional genomics, and biomarker development.
For more information, please contact:
Dr. Don Very, at 203-315-5980 or donald.very@iba-analytics.com or visit http://www.iba-analytics.com.
|
